TKIs inhibit the signal transduction pathways of aberrant tyrosin kinases p210 and p190 encoded by the aberrant fusion gene Breakpoint cluster region protein/Abelson murine leukemia viral oncogene homolog 1 (BCR/ABL) which favor blasts proliferation, apoptosis inhibition, and response to regulation factors [131].These drugs can inhibit several targets such as c-KIT, Platelet-derived growth factor (PDGF) but only dasatinib interferes also with ephrin receptor (EPH) and Src kinase that are overexpressed on tumor cells. The gene discussed is KIT; the disease is neoplasm.